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Aims To identify distinct trajectories of fatigue over a 12-month period and to examine their impact on mortality in chronic
heart failure (CHF).
Methods
and results
Consecutive CHF patients (n ¼ 310) were assessed at baseline and at 2- and 12-month follow-up for symptoms of
exertion and general fatigue. Latent growth mixture modelling was used to examine the course of fatigue over time.
The endpoint was mortality following the 12-month assessment of fatigue. Over the initial 12-month follow-up, six
distinct trajectories for exertion fatigue and four distinct trajectories for general fatigue were identiﬁed. Beyond the
12-month follow-up (mean follow-up period, 693 days), 50 patients (17%) had died. After controlling for standard
risk factors and disease severity, both severe exertion fatigue [hazards ratio (HR) ¼ 2.59, 95% conﬁdence interval
(CI): 1.09–6.16, P ¼ 0.03] and severe general fatigue (HR ¼ 3.20, 95% CI: 1.62–6.31, P ¼ 0.001) trajectories pre-
dicted an increased mortality rate (29 vs. 19% and 28 vs. 14%, respectively). The low exertion fatigue trajectory
was associated with a decreased mortality risk (3 vs. 19%, HR ¼ 0.12, 95% CI: 0.02–0.93, P ¼ 0.04).
Conclusion Fatigue trajectories varied across CHF patients and had a differential effect on mortality. Persistent severe fatigue was
a predictor of poor prognosis. These results may help identify distinct groups of CHF patients with potentially differ-
ential risks of adverse health outcomes.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
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Introduction
Fatigue is considered one of the key symptoms in chronic heart
failure (CHF), as symptoms of fatigue to a large extent determine
the patient’s quality of life.
1 Moreover, it has also been suggested
that symptoms of fatigue may be associated with poor cardiovascu-
lar outcomes in CHF.
2–5
ResearchonfatigueinCHFhasprimarilyfocusedonitspathophy-
siological underpinnings
6,7 and its determinants.
3,8–13 It has been
suggested that chronic, low-grade haemodynamic stress as seen in
CHF may lead to dominance of catabolic processes, which in turn
leads to skeletal myopathy, causing the sensation of fatigue.
6,7
Other studies have identiﬁed symptoms of dyspnoea, symptoms of
depression, and personality factors as important determinants of
fatigue in CHF.
11–14 Nonetheless, fatigue is still beyond complete
comprehension, and it is unlikely that the factors mentioned above
fully explain individual differences in fatigue.
Fatigue is highly prevalent among CHF patients, and progression
of CHF is on par with an increase in symptoms of fatigue.
1,3,4,11
However, the evolution of fatigue over time is not the same for
all patients with CHF. It may be important to distinguish distinct
developmental trajectories of fatigue in CHF, as knowledge of
fatigue trajectories, their clinical and psychological determinants,
and their prognostic impact allow for the identiﬁcation of high-risk
CHF patients who may need additional clinical care above and
beyond the standard medical management of the disease.
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European Journal of Heart Failure (2010) 12, 841–848
doi:10.1093/eurjhf/hfq075Since the course of fatigue has not been studied in CHF patients,
the current study’s objective was to examine (i) the course and
predictors of fatigue in CHF during a 12-month period and (ii)
their prognostic impact beyond the 12-month follow-up.
Methods
Patients
Thisstudyincluded310CHFpatientswithsystolicheartfailureandaleft
ventricular ejection fraction (LVEF) ≤40%, attending the heart failure
outpatientclinicofthetertiaryTweeStedenhospital,Tilburg,TheNeth-
erlands.Ofthe424patientswhowereinitiallyidentiﬁedaseligibletopar-
ticipateinthestudybetweenOctober2003andJune2006,46refusedto
participate.Intotal,44patientsdiedduringtheﬁrstyearofthestudy,and
24patientshadmissingquestionnairedataontwoormoremeasurement
points.Thisleft310patientsforinclusioninthepresentstudy.Thestudy
exclusion criteria were: patients aged ≥80 years, myocardial infarction
(MI) in the month prior to inclusion, other life-threatening diseases,
andinsufﬁcientunderstandingofthespokenandwrittenDutchlanguage.
Patients with diastolic heart failure were also excluded from the study
because of their hearts’ intact pump function during systole and dimin-
ished ﬁlling capacity during diastole.
Patients completed a take-home questionnaire at baseline and then
at 2- and 12-month follow-up. The study protocol was approved by
the local medical Ethics Committee in Tilburg, The Netherlands. The
study was conducted to conform to the Helsinki Declaration and
every patient provided written informed consent.
Symptoms of fatigue
Previous research suggests that it is important to differentiate between
exertion and general fatigue,
12 the former referring to fatigue directly
related to the performance of activities of daily living and the latter to
an overwhelming, sustained sense of exhaustion that does not necess-
arily relate to exertion. The Dutch Exertion Fatigue Scale (DEFS) was
used to assess exertion fatigue.
15 The DEFS consists of nine items
which are answered with ﬁve response alternatives ranging from 0
(no) to 4 (yes). Cronbach’s a for this scale is high (a ¼ 91). The
Fatigue Assessment Scale (FAS) was used to assess symptoms of
general fatigue.
16 This questionnaire consists of 10 items, which are
answered on a ﬁve-point Likert scale, ranging from 0 (never) to 4
(always). The reliability of this instrument is high (a ¼ 0.90).
Demographic and clinical variables
Demographic variables included sex, age, marital status, and edu-
cational level. Clinical variables comprised LVEF, NYHA functional
class, CHF aetiology, diabetes mellitus, hypertension, hypercholestero-
laemia, co-morbidities [stroke, chronic obstructive pulmonary disease,
peripheral arterial disease (PAD), and renal insufﬁciency], cardiac
history [MI, percutaneous coronary intervention (PCI), and coronary
artery bypass graft], smoking status, physical inactivity, body mass
index (BMI), cardiac medication, and psychotropic medication. Exer-
cise capacity was measured by means of the 6 min walking test
(walking small circuits of 52 m), which was carried out within the hos-
pital as part of this study. Patients were instructed to walk at a normal
pace and to continue walking until they were told to stop or until they
experienced too many adverse symptoms. Patients were not encour-
aged to walk as far as possible because the test was meant to reﬂect
daily life exercise capacity. Information on clinical variables was
obtained from the medical records and from the treating cardiologist
or heart failure nurse.
Mortality beyond 12-month follow-up
Patients’ hospital real-time medical records were used to assess cardi-
ovascular mortality since the 12-month follow-up. The mean duration
of follow-up counting from 12 months after baseline was 693 days
(range 74–1516 days).
Statistical analyses
Prior to statistical analyses, age (,60 vs. ≥60 years), educational level
(low vs. higher), marital status (partner vs. no partner), LVEF (,30 vs.
≥30%), NYHA functional class (I/II vs. III/IV), CHF aetiology (ischaemic
vs. non-ischaemic), co-morbidities (present vs. not present), cardiac
history (present vs. not present), and exercise capacity (,300 vs.
≥300 m) were re-coded into dichotomous variables.
Latent class (LC) regression analysis was employed to examine tra-
jectories of fatigue symptoms in CHF patients over a 12-month
period.
17 Although the general approach has been to study the
course of symptoms in a single group, LC regression allows us to
study subgroups of patients with varying courses of fatigue over
time. Therefore, a ﬁnite mixture model was ﬁtted to identify classes
of individuals following similar patterns of behaviour over time. The
model assumes unobserved latent variables to explain the associations
among observed scores and can be seen as a categorical equivalent of
factor analysis. One of the problems with ﬁtting these types of LC
models is that the categorization into classes is dominated by the
overall symptom levels, which makes it less likely that the model
picks up symptom changes. A way to overcome this problem is the
inclusion of a random intercept.
18
To determine the optimal number of trajectories, the Aiken Infor-
mation Criterion 3 (AIC3) was used, with a higher AIC3 indicating a
better ﬁt. However, a difference of less than three will favour the
least complex model. Recent studies have shown that AIC3 is a
better criterion than BIC (Bayesian Information Criterion) and AIC
in determining the number of LCs in LC models.
19,20
For comparison between classes, we used the x
2 test for discrete
variables. Adjusted standardized residuals (ASRs) were used to identify
groups responsible for signiﬁcant differences. A residual greater than
2.0 was taken to indicate a signiﬁcantly higher frequency, and a residual
less than 22.0 was considered to indicate a signiﬁcantly lower fre-
quency, than expected if the independence hypothesis was true.
21
Variables that were signiﬁcant in the univariate x
2 analyses were
entered into a multivariate multinomial logistic regression model to
assess whether demographic, medical, and psychological variables
were predictors of trajectories of symptoms of fatigue.
Cox’s proportional hazards regression was used to assess whether
fatigue trajectories predicted mortality beyond the 12-month
follow-up. In multivariate Cox’s regression, we included age, gender,
BMI, physical inactivity, diabetes mellitus, and a measure of disease
severity (LVEF) because of their relation with cardiovascular prognosis
and fatigue. The LC cluster analysis was performed with the LCA
program Latent GOLD.
17 All other data were analysed using SPSS
15.0.1 for Windows. A similar approach has previously been used in
MI,
22 PCI,
23 and PAD patients.
14
Results
Trajectories of exertion fatigue
Figure 1 displays the six distinct developmental trajectories for
exertion fatigue. The AIC3 improved from one class of exertion
fatigue (AIC3 ¼ 26353) to six classes of exertion fatigue
(AIC3 ¼ 25899), whereas a relative decline was observed in the
O.R.F. Smith et al. 842seven class model (AIC3 ¼ 25903). Compared with the ﬁve-class
model (AIC3 ¼ 25915), the six-class model achieved a signiﬁcant
improvement in ﬁt. The six-class model was therefore adopted for
further analysis.
The exertion fatigue ﬁrst class (12.6% of the sample) was classi-
ﬁed as the low exertion fatigue group and was stable over time
(intercept ¼ 1.69, P , 0.001; slope ¼ 20.0054, P ¼ 0.76). The
level of exertion fatigue in the second class (21.9%) was slightly
higher than in the ﬁrst class and stable over time (intercept ¼
5.91, P , 0.001; slope ¼ 20.011, P ¼ 0.72), and was therefore
classiﬁed as the mild exertion fatigue group. Class three (31.0%)
had a moderate offset with an observed mean DEFS score at base-
line of 19.94 [95% conﬁdence interval (CI): 18.61–21.27] but
showed a signiﬁcant decrease in exertion fatigue over time
(intercept ¼ 18.87, P , 0.001; slope ¼ 20.28, P ¼ 0.004). Since
the third class comprised the largest group of patients, it was con-
ceptualized as the reference group in the present study. The fourth
class (6.5%) was described as increasingly fatigued with a mild
offset (observed mean baseline DEFS score ¼ 8.40, 95% CI:
6.50–10.30; model intercept ¼ 8.07, P , 0.001; slope ¼ 0.74,
P , 0.001). Class ﬁve (16.8%) had an increase in exertion fatigue
and a moderate offset (observed mean baseline DEFS score ¼
16.33, 95% CI: 14.06–18.60; model intercept ¼ 17.03, P , 0.001;
slope ¼ 0.31, P ¼ 0.05). Finally, the sixth class (11.3%) was classi-
ﬁed as severely fatigued across all assessment points (intercept ¼
31.45, P , 0.001; slope ¼ 20.006, P ¼ 0.92).
Trajectories of general fatigue
The levels of general fatigue were relatively stable over time for
most patients (Figure 2). The AIC3 improved from one class of
general fatigue (AIC3 ¼ 25863) to four classes of general fatigue
(AIC3 ¼ 25741), whereas a relative decline was observed in the
ﬁve-class model (AIC3 ¼ 25749). Compared with the three-class
model (AIC3 ¼ 25745), the four-class model achieved a signiﬁ-
cant improvement in ﬁt. A four-class model for general fatigue
was therefore adopted for further analysis.
The ﬁrst class (29.4% of the sample) was classiﬁed as the low
general fatigue group and was stable over time (intercept ¼ 8.55,
P , 0.001; slope ¼ 20.095, P ¼ 0.06). The second class (45.5%)
had fairly stable moderate levels of fatigue and was conceptualized
as the reference group since this class comprised the largest group
of patients (intercept ¼ 15.10, P , 0.001; slope ¼ 20.090, P ¼
0.04). The third class (6.8%) was described as increasingly fatigued
with a mild offset (observed mean baseline FAS score ¼ 12.05,
95% CI: 9.84–14.26; model intercept ¼ 13.13, P , 0.001;
slope ¼ 0.71, P , 0.001). Finally, the fourth class (18.4%) was
classiﬁed as severely fatigued across all assessment points
(intercept ¼ 22.50, P , 0.001; slope ¼ 20.10, P ¼ 0.06).
Baseline characteristics stratiﬁed
by fatigue class
There were a number of differences in demographic, clinical, and
psychological characteristics at baseline as a function of exertion
fatigue class (Table 1) and general fatigue class (Table 2). Departure
from independence was most pronounced in the extreme exertion
fatigue groups (Table 1, numbers in bold). Patients in the low exer-
tion fatigue group were younger (ASR ¼ 23.6) and were less likely
to be obese (ASR ¼ 22.2), diabetic (ASR ¼ 22.9), have a low
exercise capacity (ASR ¼ 24.2), a higher NYHA class
(ASR ¼ 23.3), or to be on diuretics (ASR ¼ 22.5). Patients in
the severe exertion fatigue group were more likely to be female
(ASR ¼ 2.9), obese (ASR ¼ 2.0), physically inactive (ASR ¼ 5.0),
to have co-morbidities (ASR ¼ 2.1), low exercise capacity
(ASR ¼ 6.3), to be on diuretics (ASR ¼ 2.6), or psychotropic
medication (ASR ¼ 5.7), and to be in a higher NYHA class
(ASR ¼ 3.8).
Figure 1 Observed trajectories of exertion fatigue.
Figure 2 Observed trajectories of general fatigue.
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only observed in the low and the severe fatigue groups (Table 2,
numbers in bold). Patients in the low general fatigue group were
less likely to be physically inactive (ASR ¼ 22.6), to be in a
higher NYHA class (ASR ¼ 22.2), to be on psychotropic medi-
cation (ASR ¼ 22.8), and to have a low exercise capacity
(ASR ¼ 24.0). Patients in the severe general fatigue group were
more likely to be smokers (ASR ¼ 3.2), to be physically inactive
(ASR ¼ 4.3), to be in a higher NYHA class (ASR ¼ 2.0), and to
have low exercise capacity (ASR ¼ 3.1).
Predictors of fatigue trajectories
Multivariate predictors of exertion fatigue trajectories are shown in
Tables 3 and 4. Multinomial logistic regression analysis revealed that
younger patients, patients without diabetes mellitus or other
co-morbidities, and patients with a preserved exercise capacity
were more likely to be in the low exertion fatigue class when com-
pared with the reference group, whereas patients in NHYA class
III/IV were less likely to be in the low exertion fatigue class
(Table 3). Furthermore, male, physically active patients without
co-morbidities or impaired exercise capacity were more likely to
be in the mild exertion fatigue class when compared with the
reference group. Finally, female, physically inactive patients on psy-
chotropic medication and with impaired exercise capacity were
more likely to be in the severe exertion fatigue group (Table 3).
Patients with a preserved exercise capacity and not on psycho-
tropic medication were more likely to be in the low general fatigue
class when compared with the reference group (Table 4). In con-
trast, patients who were physically inactive smokers were more
likely to be in the severe general fatigue class. An additional analysis
controlling for disease severity (LVEF) did not alter the results
reported in Tables 3 and 4.
Trajectories of fatigue and chronic heart
failure prognosis
The mean follow-up period was 28.3 months (SD ¼ 11.8). During
this period, 50 patients (16.6%) died. The exertion fatigue classes
had the following event rates: reference group (18.8%, n ¼ 18),
low exertion fatigue (2.6%, n ¼ 1), mild exertion fatigue (14.7%,
n ¼ 10), increased exertion fatigue with mild offset (15.0%, n ¼
3), increased exertion fatigue with moderate offset (15.4%, n ¼
...............................................................................................................................................................................
Table 1 Baseline characteristics stratiﬁed by exertion fatigue class
a
Variable,% (n) Total Low
exertion
fatigue
(n 5 39)
Mild
exertion
fatigue
(n 5 68)
Reference
group
(n 5 96)
Increased
exertion
fatigue with
mild offset
(n 5 20)
Increased
exertion
fatigue with
moderate
offset (n 5 52)
Severe
exertion
fatigue
(n 5 35)
P-value
Male sex 70.0 (217) 82.1 (32) 85.3 (58) 64.6 (62) 65.0 (13) 67.3 (35) 48.6 (17) ,0.001
Age ≥ 60 72.6 (225) 48.7 (19) 72.1 (49) 76.0 (73) 85.0 (17) 75.0 (39) 80.0 (28) 0.01
Having no partner 71.3 (221) 79.5 (31) 80.9 (55) 66.7 (64) 60.0 (12) 69.2 (36) 65.7 (23) 0.20
Low educational level 15.2 (47) 17.9 (7) 22.1 (15) 12.5 (12) 25.0 (5) 9.6 (5) 8.6 (3) 0.21
Smoking 22.6 (70) 17.9 (7) 22.1 (15) 19.8 (19) 15.0 (3) 32.7 (17) 25.7 (9) 0.44
Obesity (BMI . 30) 27.7 (86) 12.8 (5) 20.6 (14) 35.4 (34) 20.0 (4) 28.8 (15) 40.0 (14) 0.03
Ischaemic aetiology 53.9 (167) 46.2 (18) 54.4 (37) 60.4 (58) 35.0 (7) 51.9 (27) 57.1 (20) 0.34
Cardiac history
b 57.1 (177) 48.7 (19) 54.4(37) 60.4 (58) 45.0 (9) 55.8 (29) 71.4 (25) 0.31
Physical inactivity 43.2 (134) 35.9 (14) 23.5 (16) 45.8 (44) 25.0 (5) 50.0 (26) 82.9 (29) ,0.001
Hypertension 37.4 (116) 15.4 (6) 41.2 (28) 37.5 (36) 40.0 (8) 40.4 (21) 48.6 (17) 0.06
Hypercholesterolaemia 47.7 (148) 35.9 (14) 45.6 (31) 53.1 (51) 30.0 (6) 55.8 (29) 48.6 (17) 0.20
Diabetes 23.9 (74) 5.1 (2) 23.5 (16) 27.1 (26) 15.0 (3) 34.6 (18) 25.7 (9) 0.03
Co-morbidities
c 35.2 (109) 23.1 (9) 26.5 (18) 43.8 (42) 20.0 (4) 34.6 (18) 51.4 (18) 0.02
LVEF , 30% 40.0 (124) 41.0 (16) 39.7 (27) 41.7 (40) 45.0 (9) 36.5 (19) 37.1 (13) 0.98
NYHA class III/IV 39.4 (122) 15.4 (6) 25.0 (17) 46.9 (45) 40.0 (8) 42.3 (22) 68.6 (24) ,0.001
ACE-inhibitors 71.9 (223) 76.9 (30) 66.2 (45) 76.0 (73) 65.0 (13) 71.2 (37) 71.4 (25) 0.72
Diuretics 73.2 (227) 56.4 (22) 73.5 (50) 76.0 (73) 80.0 (16) 65.4 (34) 91.4 (32) 0.01
b-Blocker 68.7 (213) 79.5 (31) 69.1 (47) 69.8 (67) 80.0 (16) 55.8 (29) 65.7 (23) 0.18
Statins 51.0 (158) 12.8 (5) 20.6 (14) 35.4 (34) 20.0 (4) 28.8 (15) 40.0 (14) 0.45
Aspirin 43.5 (135) 48.7 (19) 50.0 (34) 43.8 (42) 30.0 (6) 34.6 (18) 45.7 (16) 0.44
Psychotropic
medication
12.6 (39) 5.1 (2) 2.9 (2) 12.5 (12) 5 (1) 13.5 (7) 42.9 (15) ,0.001
6MWT , 300 m 41.6 (129) 10.3 (4) 19.1 (13) 49.0 (47) 30.0 (6) 51.9 (27) 91.4 (32) ,0.001
6MWT, 6 min walk test.
aNumbers in bold represent an absolute adjusted standardized residual .2.0.
bHistory of MI, CABG, and PCI.
cStroke, chronic obstructive pulmonary disease, peripheral arterial disease, and renal insufﬁciency.
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Table 2 Baseline characteristics stratiﬁed by general fatigue class
a
Variable Total Low general
fatigue (n 5 91)
Reference group
(n 5 141)
Increased general fatigue
with mild offset (n 5 21)
Severe general
fatigue (n 5 57)
P-value
Male sex 70.0 (217) 75.8 (69) 70.2 (99) 66.7 (14) 61.4 (35) 0.31
Age ≥ 60 72.6 (225) 70.3 (64) 74.5 (105) 76.2 (16) 70.2 (40) 0.85
Having no partner 71.3 (221) 74.7 (68) 72.3 (102) 57.1 (12) 68.4 (39) 0.41
Low educational level 15.2 (47) 20.9 (19) 14.2 (20) 19.0 (4) 7.0 (4) 0.13
Smoking 22.6 (70) 18.7 (17) 19.1 (27) 19.0 (4) 38.6 (22) 0.02
Obesity (BMI . 30) 27.7 (86) 24.2 (22) 27.7 (39) 28.6 (6) 33.3 (19) 0.69
Ischaemic aetiology 53.9 (167) 47.3 (43) 57.4 (81) 47.6 (10) 57.9 (33) 0.39
Cardiac history
b 57.1 (177) 50.5 (46) 60.3 (85) 42.9 (6) 64.9 (37) 0.15
Physical inactivity 43.2 (134) 31.9 (29) 40.4 (57) 42.9 (9) 68.4 (39) ,0.001
Hypertension 37.4 (116) 35.2 (32) 37.6 (53) 38.1 (8) 40.4 (23) 0.94
Hypercholesterolaemia 47.7 (148) 42.9 (39) 49.6 (70) 57.1 (12) 47.4 (27) 0.61
Diabetes 23.9 (74) 19.8 (18) 22.0 (31) 33.3 (7) 31.6 (18) 0.26
Co-morbidities
c 35.2 (109) 35.2 (32) 37.6 (53) 19 (4) 35.1 (20) 0.43
LVEF , 30% 40.0 (124) 37.4 (34) 42.6 (60) 38.1 (8) 38.6 (22) 0.87
NYHA class III/IV 39.4 (122) 29.7 (27) 40.4 (57) 42.9 (9) 50.9 (29) 0.05
ACE-inhibitors 71.9 (223) 68.1 (62) 73.0 (103) 81.0 (17) 71.9 (41) 0.66
Diuretics 73.2 (227) 67.0 (61) 75.9 (107) 71.4 (15) 77.2 (44) 0.43
b-Blocker 68.7 (213) 73.6 (67) 68.1 (96) 61.9 (13) 64.9 (37) 0.60
Statins 51.0 (158) 50.5 (46) 54.6 (77) 57.1 (12) 40.4 (23) 0.30
Aspirin 43.5 (135) 38.5 (35) 46.8 (66) 57.1 (12) 38.6 (22) 0.29
Psychotropic
medication
12.6 (39) 4.4 (4) 15.6 (22) 9.5 (2) 19.3 (11) 0.03
6MWT , 300 m 41.6 (129) 24.2 (22) 46.1 (65) 38.1 (8) 59.6 (34) ,0.001
6MWT, 6 min walk test.
aNumbers in bold represent an absolute adjusted standardized residual .2.0.
bHistory of MI, CABG, and PCI.
cStroke, chronic obstructive pulmonary disease, peripheral arterial disease, and renal insufﬁciency.
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Table 3 Multivariate predictors of fatigue class: exertion fatigue class
a
Variable Low exertion
fatigue
Mild exertion
fatigue
Increased
exertion fatigue
with mild offset
Increased
exertion fatigue
with moderate
offset
Severe exertion
fatigue
OR P-value OR P-value OR P-value OR P-value OR P-value
Male sex 2.56 0.08 3.32 0.006 NS NS NS NS 0.40 0.08
Age ≥ 60 0.35 0.02 NS NS NS NS NS NS NS NS
Obesity (BMI . 30) NS NS NS NS NS NS NS NS NS NS
Physical inactivity NS NS 0.41 0.02 NS NS NS NS 6.71 0.001
Diabetes 0.21 0.05 NS NS NS NS NS NS NS NS
Co-morbidities
b 0.31 0.02 0.44 0.03 0.33 0.07 NS NS NS NS
NYHA class III/IV 0.32 0.04 0.48 0.06 NS NS NS NS NS NS
Diuretics NS NS NS NS NS NS NS NS NS NS
Psychotropic medication NS NS 0.22 0.07 NS NS NS NS 5.43 0.003
6MWT , 300 m 0.22 0.02 0.39 0.02 NS NS NS NS 9.62 0.001
6MWT, 6 min walk test.
aSigniﬁcant levels .0.1 are displayed as NS, i.e. not signiﬁcant.
bStroke, chronic obstructive pulmonary disease, peripheral arterial disease, and renal insufﬁciency.
Bold entries indicate statistical signiﬁcance at the P , 0.05 level.
Course of fatigue in CHF 8458), and severe exertion fatigue (28.6%, n ¼ 10). For the general
fatigue classes, the event rates were: reference group (13.5%,
n ¼ 19), low general fatigue (12.1%, n ¼ 11), increased general
fatigue with mild offset (19.0%, n ¼ 4), and severe general fatigue
(28.1%, n ¼ 16). Older age, being physically active, and a lower
LVEF were associated with a higher incidence of mortality
(Table 5). Obesity showed a trend towards signiﬁcance. Of note,
being physically active was only signiﬁcantly associated with mor-
tality in the multivariate analysis and may therefore represent a
suppressor effect.
A ﬁrst Cox’s regression model showed that both low exertion
fatigue and severe exertion fatigue predicted mortality beyond
........................... .......................................................... .............................
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Table 4 Multivariate predictors of fatigue class: general fatigue class
a
Variable Low general fatigue Increased general fatigue with mild offset Severe generalfatigue
OR P-value OR P-value OR P-value
Smoking NS NS NS NS 3.03 0.002
Physical inactivity NS NS NS NS 2.96 0.002
NYHA class III/IV NS NS NS NS NS NS
Psychotropic medication 0.28 0.03 NS NS NS NS
6MWT , 300 m 0.42 0.007 NS NS NS NS
6MWT, 6 min walk test.
aSigniﬁcant levels .0.1 are displayed as NS, i.e. not signiﬁcant.
Bold entries indicate statistical signiﬁcance at the P , 0.05 level.
................................................................................
Table 5 Trajectories of fatigue and chronic heart
failure prognosis (multivariate)
Variable HR 95% CI P-value
Model including exertion fatigue
Male sex 1.67 0.85–3.31 0.14
Age ≥ 60 3.23 1.26–8.26 0.01
Obesity (BMI . 30) 0.48 0.23–1.02 0.06
Physical inactivity 0.43 0.21–0.85 0.02
Diabetes 1.23 0.63–2.37 0.55
LVEF , 30% 2.17 1.22–3.87 0.009
Low exertion fatigue 0.12 0.02–0.93 0.04
Mild exertion fatigue 0.59 0.27–1.32 0.20
Increased exertion fatigue with
mild offset
0.65 0.19–2.21 0.49
Increased exertion fatigue with
moderate offset
1.03 0.44–2.41 0.95
Severe exertion fatigue 2.59 1.09–6.16 0.03
Model including general fatigue
Male sex 1.22 0.63–2.36 0.55
Age ≥ 60 3.70 1.45–9.47 0.006
Obesity (BMI . 30) 0.53 0.25–1.15 0.11
Physical inactivity 0.56 0.31–1.02 0.06
Diabetes 1.26 0.64–2.46 0.51
LVEF , 30% 2.20 1.24–3.90 0.007
Low general fatigue 0.89 0.42–1.89 0.75
Increased general fatigue with mild
offset
1.71 0.58–5.07 0.33
Severe general fatigue 3.20 1.62–6.31 0.001
Bold entries indicate statistical signiﬁcance at the P , 0.05 level.
Figure 3 Event-free survival stratiﬁed by exertion fatigue class
(A) and general fatigue class (B).
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the reference group (mortality rate ¼ 19%), patients in the low
exertion fatigue class had a decreased mortality rate [3%,
hazards ratio (HR) ¼ 0.12, 95% CI: 0.02–0.93, P ¼ 0.04) and
those in the severe exertion fatigue class an increased mortality
rate (29%, HR ¼ 2.59, 95% CI: 1.09–6.16, P ¼ 0.03). A second
Cox’s regression model showed that severe general fatigue pre-
dicted mortality beyond the 12-month follow-up (Table 5 and
Figure 3B). Patients in the severe general fatigue class had an
increased risk for mortality when compared with the reference
group (mortality rate ¼ 28 vs. 14%, HR ¼ 3.20, 95% CI: 1.62–
6.31, P ¼ 0.001).
An additional analysis controlling for the use of psychotropic
medication (P . 0.5 in both models) did not signiﬁcantly alter
the model results displayed in Table 5. A ﬁnal analysis showed
that when exertion fatigue and general fatigue were entered in
the multivariate model simultaneously, both severe exertion
fatigue (HR ¼ 2.90, 95% CI: 1.14–7.36, P ¼ 0.03) and severe
general fatigue (HR ¼ 3.00, 95% CI: 1.47–6.14, P ¼ 0.003)
remained signiﬁcant predictors of mortality. Similarly, the protec-
tive effect of low exertion fatigue (HR ¼ 0.12, 95% CI: 0.02–
0.99, P ¼ 0.05) remained signiﬁcant as well. This result suggests
that independently from each other, both types of fatigue add to
the risk of mortality in CHF.
Discussion
To our knowledge, this is the ﬁrst study to examine the course of
symptoms of fatigue in patients with CHF. Similar to previous
studies,
5,12 we differentiated between exertion and general
fatigue and found six distinct trajectories for exertion fatigue and
four distinct trajectories for general fatigue. Multinomial logistic
regression analysis revealed that sex, age, physical inactivity, dia-
betes mellitus, co-morbidities, NYHA class, exercise capacity,
and psychotropic medication were predictors of exertion fatigue,
varying according to fatigue classes. Predictors of general fatigue,
again varying according to fatigue classes, comprised smoking,
physical inactivity, and exercise capacity. Cox’s regression
showed that patients in the severe exertion fatigue class and
severe general fatigue class independently had an almost three-fold
increased risk for mortality when compared with the reference
group. Patients in the low exertion fatigue group had a decreased
risk for mortality.
Fatigue is considered as one of the most important symptoms
affecting patients’ quality of life. However, fatigue remains under-
recognized in clinical practice,
24,25 as well as an unresolved issue
in CHF.
12 In the current study, we were able to further reﬁne
our understanding of the course of fatigue in CHF and to charac-
terize most of the trajectories by means of baseline variables.
Overall, patients with low/mild levels of exertion/general fatigue
were characterized by relatively good physical health (no diabetes
mellitus, no co-morbidities, no physical inactivity, and good exer-
cise capacity) and psychological health (no psychotropic medi-
cation), whereas the opposite was true for patients with high
levels of fatigue. Age and gender effects were found for exertion
fatigue. However, we were unable to describe the trajectories
that showed an increase in fatigue over time (increased exertion
fatigue with mild offset, increased exertion fatigue with moderate
offset, and increased general fatigue with mild offset). An
explanation for this could be that (i) the groups were relatively
small and therefore lacked statistical power to reveal signiﬁcant
differences, (ii) the overall response levels of fatigue in these
trajectories were more similar to the reference group when
compared with the more extreme groups, resulting in smaller
differences with respect to baseline variables, and (iii) persistence
of fatigue is more important with regard to prognosis when
compared with changes in fatigue over time.
From a clinical point of view, knowledge about factors charac-
terizing trajectories that display changes in fatigue over time is
important as they identify targets for intervention. Importantly,
the ﬁndings of the present study indicate that fatigue trajectories
are differently related to an increase or decrease in mortality
rate. This ﬁnding provides further fuel to the ‘debate’ about
whether the experience of fatigue is an important factor in itself
or merely an unwelcome by-product of disease progression.
26 In
previous studies, we have shown that fatigue was associated with
rehospitalization
2 and with the combined endpoint of rehospitali-
zation and death.
5 The problem with rehospitalization as an
outcome measure is its semi-objective nature, since the decision
to rehospitalize is not solely based on objective diagnostic
measures but also on symptom presentation and symptom
interpretation. Therefore, it is important to note that in the
present study, both exertion and general fatigue independently
predicted mortality in CHF, above and beyond disease severity
and other clinical risk factors. Large-scale studies should give a
more in-depth insight into the differential effect of the fatigue tra-
jectories on mortality.
The mechanisms through which fatigue may exert its effect on
mortality are unclear. Future studies should assess physiological
measures that are known to be abnormal in CHF patients and
that are relevant with respect to fatigue, e.g. measures of abnormal
muscle metabolism and an enhanced ergo reﬂex response;
6,7
inﬂammatory markers may also be an interesting avenue for
research in this regard.
27,28 Increased fatigue may also have
impact on the patient’s ability for self-care, which has been associ-
ated with poor prognosis in CHF.
29
The results of the present study advocate the use of a latent
growth mixture modelling approach in clinical cardiology research,
because it allows for the identiﬁcation of subgroups with distinct
developmental patterns. As such, this approach provides additional
information beyond that obtained from studying prevalence rates
or change scores. An LC approach has been used in previous
studies,
14,22,23,30,31 however, without the inclusion of a random
intercept. Similar to our studies, these studies also found
support for multiple rather than single trajectories, although
they examined depressive symptoms,
14,22,30 anxiety,
23 and quality
of life,
31 but not fatigue.
This study has a number of limitations. First, the cardiologist or
heart failure nurses asked patients to participate in the study, and
this interaction pattern might have inﬂuenced patient selection.
Secondly, the examined predictors of the fatigue trajectories
were only assessed once. Thirdly, we did not include a control
group of patients suffering from fatigue without CHF. Fourthly,
the number of events was relatively small when compared with
Course of fatigue in CHF 847the number of LCs. This might have resulted in less reliable risk
estimates. Nevertheless, the strengths of the current study were
the repeated assessment of fatigue over time, the prospective
design examining the course of fatigue over time using a
state-of-the-art modelling approach, and the use of an objective
medical outcome. Within the sampling frame as deﬁned in the
method section, we were able to collect a representative sample
of systolic CHF patients. Finally, we used reliable and valid
measures of both exertion and general fatigue.
In summary, we found six distinct trajectories for exertion
fatigue and four distinct trajectories for general fatigue in patients
with CHF. Several predictors, varying according to fatigue
classes, were identiﬁed, with age, sex, physical inactivity,
co-morbidities, exercise capacity, and psychotropic medication
use being the most prominent ones. Severe exertion fatigue and
severe general fatigue independently predicted an increased mor-
tality risk beyond the 12-month follow-up, whereas low exertion
fatigue was associated with a decreased mortality risk. Given that
this was the ﬁrst study to examine the course of fatigue in CHF
patients, future studies are warranted to conﬁrm these ﬁndings
in larger samples with more frequent measures of fatigue and a
longer follow-up. The results of the present study may help identify
distinct groups of patients with potentially differential risks of
adverse health outcomes, guide future interventions, and therefore
be valuable for both research and clinical practice.
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